Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 2, 2009, Pages 175-182

  Puglisi, Fabio ^a   Deroma, Laura ^a   Russo, Stefania ^a   Cartenì, Giacomo ^b   Sporchia, Andrea ^c   Ucci, Giovanni ^d   De Signoribus, Giorgio ^e   Del Prete, Salvatore ^f   Vecchione, Aldo ^g   Pinotti, Graziella ^h   Beccaglia, Patrizia ⁱ  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d A MANZONI HOSPITAL   (Italy)

^e Madonna del Soccorso Hospital   (Italy)

^f SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h OSPEDALE DI CIRCOLO   (Italy)

ⁱ Janssen Cilag SpA Italia   (Italy)

Author keywords

Anemia; Elderly patients; Epoetin alfa; Quality of life; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; AGE; AGED; ANEMIA; ASTHENIA; BLOOD TRANSFUSION; CANCER PATIENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GRANULOCYTOPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PROSPECTIVE STUDY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

AGE FACTORS; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 58149213987     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.07.010     Document Type: Review

References (18)

1. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 (1998) 43-46
2. Ludwig H., and Fritz E. Anemia in cancer patients. Semin Oncol 25 (1998) 2-6
3. Sobrero A., Puglisi F., Guglielmi A., et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 28 (2001) 15-18
4. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., and Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (1997) 1218-1234
5. Demetri G.D., Kris M., Wade J., Degos L., and Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (1998) 3412-3425
6. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., and Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19 (2001) 2875-2882
7. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin Alfa Study Group. J Clin Oncol 19 (2001) 2865-2874
8. Witzig T.E., Silberstein P.T., Loprinzi C.L., et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23 (2005) 2606-2617
9. Ania B.J., Suman V.J., Fairbanks V.F., Rademacher D.M., and Melton III L.J. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 45 (1997) 825-831
10. Chaves P.H., Ashar B., Guralnik J.M., and Fried L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women: should the criteria currently used to define anemia in older people be reevaluated?. J Am Geriatr Soc 50 (2002) 1257-1264
11. Cartenì G., Giannetta L., Ucci G., et al. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer 15 (2007) 1057-1066
12. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (1997) 13-19
13. Cascinu S., Del Ferro E., Fedeli A., Ligi M., Alessandroni P., and Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology 52 (1995) 422-426
14. Gebbia V., Di Marco P., and Citarrella P. Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin. Crit Rev Oncol Hematol 48 (2003) S49-55
15. Massa E., Madeddu C., Lusso M.R., Gramignano G., and Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57 (2006) 175-188
16. Boccia R., Malik I.A., Raja V., et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 11 (2006) 409-417
17. Aapro M., Leonard R.C., Barnadas A., et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the breast cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol 26 (2008) 592-598
18. Khuri F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356 (2007) 2445-2448